Coronavirus cell in microscopic view. Virus Immunotherapy

SNAP Cancer Vaccine Platform

SNAP Cancer Vaccine Platform

A New Approach for
Short Peptide Cancer Vaccines

SNAP liposomes contain synthetic MPLA, QS-21 and Cobalt porphyrin phospholipid (CoPoP)

CoPoP enables liposomes to stably bind short MHC-I epitopes upon admixture.

Better delivery of epitopes and adjuvants to immune cells in draining lymph nodes

Induce higher frequency of antigen specific CD8+ T cells with > 10,000X lower peptide dosing 

Murine RENCA neoepitope kidney cancer model
Murine RENCA neoepitope kidney cancer model

Effective anti-tumor treatment

Nanograms of peptide reverse established and metastatic tumor growth in TC-1 tumor model

Other cancer models show synergy with checkpoint blockade inhibition and other anti-tumor treatments 

Murine TC-1 HPV antigen cancer model
Murine TC-1 HPV antigen cancer model

 

Find the needle in the haystack

 

SNAP is ideal for multivalent immunization.

Short peptide microlibraries with SNAP enables finding functional neoepitopes from candidate lists.

• SNAP vaccines are functional even when 59 irrelevant peptides are mixed with a single functional  neoepitope.

 

SNAP finds functional neoepitopes. A single functional one still works when mixed with 59 irrelevant ones
SNAP finds functional neoepitopes. A single functional one still works when mixed with 59 irrelevant ones

 

Make self-antigens immunogenic

 

Self-antigens typically are poorly immunogenic

SNAP allows unbiased determination of mutated epitopes with enhanced function using a two-step microlibrary screening method

• Success rate of enhanced epitope selection is ~50%. 10 identified so far against 3 target murine epitopes (Trp-2, AH1, WT1).

Finding an improved Trp2 epitope in murine B16F10 melanoma model
Finding an improved Trp2 epitope in murine B16F10 melanoma model

 

Path for human testing

 

• CoPoP made by POP BIO produced under GMP at 2.5M dose scale. Other components obtainable under GMP.

• CoPoP GLP toxicity report available.

• CoPoP is part of EuCorVac-19, tested in a 280 person ph1/2 trial.

•Testing framework for human epitopes

 

SNAP has been clinically validated as part of ongoing Phase I/II clinical studies of the EuCorVac-19 vaccine against COVID-19.

POP BIO is actively seeking partners interested in collaborating with the SNAP technology, reach out to us for more information.